Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
- Written by PR Newswire Asia - Asian Spectator
MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The LanCL family of proteins are responsive to...




